Drug Cos. Made Record Pay-For-Delay Deals In 2011: FTC

Law360, New York (October 25, 2011, 1:41 PM EDT) -- Pharmaceutical companies racked up record numbers of so-called reverse payment patent settlements in 2011 designed to delay the release of a rival generic drug, the Federal Trade Commission said Tuesday, calling it an anti-competitive practice that costs consumers and the U.S. government billions.

Drug companies entered into 28 potential pay-for-delay deals in fiscal year 2011 — from Oct. 1, 2010, to Sept. 30 — nearly matching last year's high of 31 deals, and higher than any other previous year since the FTC began collecting industry data...
To view the full article, register now.